The company confirmed it is assessing strategic options in coordination with its majority shareholder, as part of its ongoing efforts to enhance long-term value creation. However, there is no certainty that this will result in a deal. PolyPeptide's response comes after Bloomberg had reported earlier that EQT, Advent and KKR were interested in a takeover. The group acknowledged the speculations, but declined to provide further comment on the media reports. PolyPeptide operates as a contract development and manufacturing organisation specialising in peptide-based active pharmaceutical ingredients, with a global footprint spanning Europe, the US, and India. The company is positioned to benefit from rising demand for peptide-based therapies, including treatments targeting obesity and diabetes, and is currently executing a turnaround strategy aimed at scaling production capacity and improving operational performance. Investor sentiment has already responded to the developments, with...
learn more
